echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > FDA grants priority review to Enhertu in lung cancer

    FDA grants priority review to Enhertu in lung cancer

    • Last Update: 2022-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    AstraZeneca and Daiichi Sankyo today announced that the U.


    Managing FDA Lung Cancer NSCLC

    The filing is based on data from the pivotal Phase II DESTINY-Lung01 trial, in which the HER2-targeting ADC demonstrated a 54.


    "Enhertu has the potential to become a new standard of care for this patient population," said Susan Galbraith, head of oncology research and development at AstraZeneca


    If approved, this would be Enhertu's third oncology indication


    If approved, this would be Enhertu's third oncology indication


     

    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5551523 https://firstwordpharma.
    com/story/5551523

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.